8-K filing — CalciMedica, Inc. (CALC)
Filed: 2026-09-02 AccNo: 0001193125-26-379419 Size: 140 KB Item 8.01: Other Events
Stocks · News reference
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-02 AccNo: 0001193125-26-379419 Size: 140 KB Item 8.01: Other Events
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.